Nancy A Kernan, Elizabeth Klein, Audrey Mauguen, Joanne Torok-Castanza, Susan E Prockop, Andromachi Scaradavou, Kevin Curran, Barbara Spitzer, Maria Cancio, Julianne Ruggiero, Jennifer Allen, Andrew Harris, Joseph Oved, Richard J O'Reilly, Jaap Jan Boelens
The clinical value of serial routine bone marrow aspirates (rBMAs) in the first year after allogeneic hematopoietic cell transplantation (alloHCT) to detect or predict relapse of acute leukemia (AL) and myelodysplastic syndrome (MDS) in pediatric and young adult patients is unclear. The purpose of this analysis was to determine if assessment of minimal residual disease (MRD) by multiparameter flow cytometry (MFC, MFC-MRD) or donor chimerism (DC) in rBMAs or serial complete blood counts (CBCs) done in the year after alloHCT predicted relapse of AL or MDS in pediatric and young adult patients...
April 20, 2024: Transplantation and cellular therapy